Interpreting clinical assays for histone deacetylase inhibitors by Martinet, Nadine & Bertrand, Philippe
© 2011 Martinet and Bertrand, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Cancer Management and Research 2011:3 117–141
Cancer Management and Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
117
Review
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CMR.S9661
interpreting clinical assays for histone  
deacetylase inhibitors
Nadine Martinet1
Philippe Bertrand2
1Laboratory of Bioactive Molecules, 
institute of Chemistry, University of 
Nice – Sophia Antipolis, Parc valrose, 
Nice, France; 2Laboratory of Synthesis 
and Reactivity of Natural Substances, 
University of Poitiers, Poitiers, France
Correspondence: Philippe Bertrand 
Laboratoire Synthèse et Réactivité 
des Substances Naturelles, UMR 6514 
CNRS – Université de Poitiers, rue  
Jacques Fort, B28, 86022, Poitiers,  
France 
Tel (33) 05 49 45 41 92 
Fax (33) 05 49 45 35 01 
email philippe.bertrand@univ-poitiers.fr
Abstract: As opposed to genetics, dealing with gene expressions by direct DNA sequence 
modifications, the term epigenetics applies to all the external influences that target the chromatin 
structure of cells with impact on gene expression unrelated to the sequence coding of DNA itself. 
In normal cells, epigenetics modulates gene expression through all development steps. When 
“imprinted” early by the environment, epigenetic changes influence the organism at an early stage 
and can be transmitted to the progeny. Together with DNA sequence alterations, DNA aberrant 
cytosine methylation and microRNA deregulation, epigenetic modifications participate in the 
malignant transformation of cells. Their reversible nature has led to the emergence of the promis-
ing field of epigenetic therapy. The efforts made to inhibit in particular the epigenetic enzyme 
family called histone deacetylases (HDACs) are described. HDAC inhibitors (HDACi) have 
been proposed as a viable clinical therapeutic approach for the treatment of leukemia and solid 
tumors, but also to a lesser degree for noncancerous diseases. Three epigenetic drugs are already 
arriving at the patient’s bedside, and more than 100 clinical assays for HDACi are registered on 
the National Cancer Institute website. They explore the eventual additive benefits of combined 
therapies. In the context of the pleiotropic effects of HDAC isoforms, more specific HDACi and 
more informative screening tests are being developed for the benefit of the patients.
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Introduction
The transcriptional state of a eukaryotic gene is determined by the surrounding chro-
matin architecture, the state of DNA cytosine methylation in the promoter/first exons 
and the associated regulating microRNAs (miRNAs).
In the cell nucleus, the genome is packaged into a superstructure, the chromatin, 
whose elementary dynamic units are the nucleosomes. Each is made up of four associ-
ated dimers of core histones (H2A, H2B, H3, and H4) around which 147 base pairs 
of DNA are wrapped, the nucleosomes being finally linked together via the linker 
histone H1 (Figure 1). Chromatin is compacted around the DNA into a so-called 
“closed state” when cells are resting. It is opened into an “active state” to allow for 
gene transcription by adenosine triphosphate (ATP)-dependent protein complexes, 
which remodel the chromatin architecture. Theses complexes modify the acces-
sibility of DNA regulatory sites through both repositioning (sliding) and ejecting 
nucleosomes. Modeling complexes include transcription co-activators, transcription 
factors, and epi-enzymes.1 Histone acetyltransferases (HATs), for instance, acetylate 
specific lysine residues of histones and convert them into an amide form, loosening 
histone contacts with DNA, resulting in exposed binding sites for the transcription Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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DNA
� 148 base pairs
Nucleosome
Linker histone H1
Octamer
histones H2A, H2B, H3, H4
N-terminal
reversible chemical modifications
of histones
Phosphorylation: Kinases � Phosphatases
Ubiquitination: Ubiquitine ligases � UBP
Acetylation: HAT � HDAC
Inactive chromatin, compacted = DNA not accessible, no transcription
Chemical modifications of histones
Active chromatin, open form = DNA accessible, transcription regulation
Methylation: HMT � HDM
Simple, double, triple, includes arginines
Figure 1 The nucleosome unit and the histone tail chemical modification. 
Abbreviations: HAT, histone acetyltransferase; HDM, histone demethylases; HDAC, histone deacetylase; HMT, histone methyltransferase; UBP, ubiquitin-specific protease.
machinery. On the other hand, other complexes function 
as gene silencers and deny the same machinery access to 
DNA. Repressive complexes include histone deacetylases 
(HDACs), which deacetylate specific lysine residues of 
the histones tails to induce tighter interactions between the 
now positively charged lysine (Nε protonated form) and the 
negatively-charged DNA phosphate groups.2 Beside acetyla-
tion, several other post-translational lysine modifications in 
histones have been described: methylation, phosphorylation, 
SUMOylation, and ATP-ribosylation.3,4
All the modifications incurred by histones form the 
  “histone code”. For example, K9 in H3 turns the chromatin into 
inactivity when methylated. Phosphorylation of serine 10 in the 
same H3 is required for methylation of K4 and acetylation of 
K9 and K14. Similar enzyme crosstalk has also been described, 
for ubiquitination of K120 in H2B prior to methylation of 
K79 in H3.5 Several epi-enzyme families are involved in the 
histones modifications. HATs and HDACs2 have balancing 
actions for histones acetylation. Methylation of histones6 is 
controlled by histones methyltransferases (HMTs) and histones 
demethylases (HDMs), while histones arginine methylation is 
catalyzed by the protein arginine N-methyltransferases family 
of enzymes.7–9 One, two, or three methylations are possible, 
with impact on gene expression/repression.10 The analysis of 
epigenetic marks at the genome-wide scale has shown that 
monomethylated H3K4 is associated with transcription factors 
binding to enhancers, trimethylated H3K4 with transcription 
start sites, and dimethylated H3K4 with both transcription start 
sites and enhancers.11
DNA methyltransferases (DNMTs) repress gene expres-
sion via DNA cytosine methylation, unfavorable to transcrip-
tion factor binding. DNMTs are recruited and stabilized, on 
DNA, by HMTs and HDMs. Both are also able to recruit 
HDACs, methyl-binding proteins like methyl CpG binding 
protein 2 (MECP2), and several co-factors to further tune 
gene expression.12,13 Since DNMT co-factors are lacking in 
normal tissues, gene re-expression induced by DNMT inhibi-
tors could be limited to tumor tissues to reduce “off-target” 
effects. DNA methylation in the epigenomes of human 
embryonic stem cells is an important field of research. The 
roles of DNA methylation in cancer genesis have also been 
extensively studied.12,13
Catalyzed by the ten-eleven translocation 1 (TET) 
  family of enzymes, DNA hydroxymethylcytosine has been 
recently described as a step towards cytosine   demethylation.14 
  Mutations and translocations of TET are present in myeloid 
malignancies.15 The role of hydroxymethylcytosine, if any, is 
not yet understood, but its existence questions all the results 
obtained so far when determining the cytosine methylation 
status.
In a further step of complexity, specialized miRNAs read 
the epi-code and target effectors genes to modulate their 
expression. MiRNAs are small non-coding RNAs of 20–22 
nucleotides that inhibit gene expression when they engage 
either in imperfect base-pairing with their target mRNA 
3′-untranslated region or affect its stability. MiRNA 29-a, -b 
and -c target DNMT3a and b directly and cell-specifically. 
HDAC4 is targeted by both miR-1 and miR-140, while 
miR-449-a targets HDAC1 in prostate malignant cells.16 
Onco-proteins like promyelocyte leukemia retinoic acid 
receptor-α (PML-RARα) in promyelocytic leukemia and 
B-cell lymphoma 6 in non-Hodgkin’s lymphoma result 
from translocations. It is near the premiR-223 region that the 
t(8;21) translocation juxtaposes the Runt-related transcription Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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factor 1 gene on chromosome 21 with the Cytochrome B 
Termination 1 gene on chromosome 8, generating the acute 
myeloid leukemia (AML)1-Eight Twenty One fusion gene.17 
The recruitment, on this chimerical site, of DNMT, MeCP2, 
and HDAC1 repressor complexes, promotes leukemogenesis. 
Epi-miRNAs write their own epi-code when their cytosines 
are methylated. Downregulation of miR-124a induces an up 
regulation of its target, cyclin-dependent kinase 6 (CDK6), as 
well as phosphorylation of retinoblastoma, and contributes to 
the abnormal proliferation of acute lymphoblastic leukemia 
(ALL) cells both in vitro and in vivo.
Most epigenetic changes translate into either up regula-
tion or silencing of gene expression.18 When inappropriate, 
they predispose the organism to more mutational events via 
increased genomic instability and aberrant cellular signaling. 
The field of epigenetic being extremely prolific, we have 
restricted our reference list to the essentials.
HDACs
HDACs remove the acetyl group from an N-ε-acetyl lysine 
located near the amino terminus of a core histone, cleaving 
an amide bond and increasing the positive charge of the 
histone. The removal of acetyl groups from the histones 
tails stabilizes nucleosomal DNA-histones interactions by 
its subsequent change in electrostatic charges. It is the basis 
for HDAC-mediated transcriptional repression via chroma-
tin condensation.19 HDACs have been categorized into four 
classes. Class I HDACs (HDAC1, 2, 3, and 8) are nuclear 
proteins with ubiquitous expression involved in regulating 
cell proliferation.20 HDAC2 has been shown to suppress 
apoptosis in tumor cells not only via both the intrinsic/ 
mitochondrial and the extrinsic/death-receptor pathways, 
but also via mitotic failure and autophagic cell death, while 
HDAC3 is involved in bone structure and S-phase check 
point.21,22 Class II HDACs have a tissue-specific expression 
and can shuttle between the nucleus and the cytoplasm. They 
are divided into two subclasses: IIa with HDAC4, 5, 7, and 9. 
HDAC4 represses chondrocyte hypertrophy. HDAC7 func-
tions in the down regulation and apoptosis of T-cells.20 
HDAC9 is involved in cardiomyocyte differentiation.23 Class 
IIb includes HDAC10 and HDAC6. The latter contains two 
tandem catalytic domains: one is for histones deacetylation 
and the other for deacetylation of α-tubulin. HDAC6 has also 
the capacity to bind directly to ubiquitinated proteins through 
an ubiquitin-binding domain, to target cargo proteins for sub-
sequent processing. HDAC6-specific effects on cell motility 
and the proteasome are thought to be responsible for much of 
the toxicity of HDACs inhibitors (HDACi). HDAC 10 and 9 
are required for chromosome homologous recombination.24 
Class III HDACs include 7 different members of the sirtuin 
(SIRT) family. They are dependent on nicotinamine adenine 
dinucleotide (NAD+) to remove the acetyl group from lysine 
residues in histones and nonhistone substrates. Resveratrol 
from grapes and red wine is a SIRT1 activator.25 HDAC11 
is the only member of Class IV .
Thus, it appears that HDAC activity depends on isoform 
types, sub cellular localization, association into   multi-protein 
complexes and even post-translational modifications. 
HDACs are also able to deacetylate nonhistone proteins   
such as transcription factors, chaperone proteins and effectors 
of DNA repair, cell-signaling and metabolism. The ongoing 
concept is that deacetylation stabilizes these proteins. HDACs 
have different developmental functions, as shown by the 
different phenotypes obtained in knockout mice.26 Disrup-
tion of HDAC1 causes early embryonic lethality. HDAC2 
knockout mice are viable but present fatal multiple cardiac 
defects. Germline HDAC3-deficiency causes embryonic 
lethality. HDAC3 conditional knockout mice gave severe 
deficits in membranous and endochondral bone formation. 
Germline deletion of HDAC4 causes premature ossifica-
tion of the developing bones. HDAC6-deficiency slightly 
enhances trabecular bone formation. HDAC7 knockout 
gave vascular defects. HDAC8 is essential for neural crest 
progenitor cell differentiation and skull bone formation.   
HDAC9 knockout mice are viable at birth but have a myocardial   
hypertrophy.
HDACs and their inhibitors
In tumor cells, deletion of a single HDAC is not sufficient to 
induce cell death but leads to nuclear bridging and fragmen-
tation, and ‘in fine’ to cell mitotic catastrophe. This suggests 
that inhibition of HDAC may be sufficient for anticancer 
activity and provides a rational incentive for the development 
of HDACi.27 In the 1970s, seminal experiments showed that 
treatment of cells with the short-chain fatty acid NaB (sodium 
butyrate) caused hyperacetylation of histone octamers and   
led to the discovery of HDACs.28 The zinc-dependent HDACs 
of classes I, II, and IV are now known to have a common 
active site made of a tubular hydrophobic channel with a 
zinc atom (Zn2+) at its end, forming the enzyme catalytic 
pocket.29 The acetyl part of the lysine substrate in histones/
proteins bind to the zinc atom while the protein four carbon 
lysine chains fits into the catalytic pocket, and deacetylation 
then follows. An HDACi is designed to block the HDAC 
catalytic activity. Several possibilities exist: irreversible or 
reversible binding to the enzyme catalytic site, competition Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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with the enzymatic substrate, and deformation of the enzyme. 
Accordingly and as shown in Figure 2, the pharmacophore 
model for HDACi includes a zinc-binding group,   competing 
somehow with the natural acetyl lysine substrate, a hydro-
phobic cap interacting with the external surface of the active 
site (generally aromatic) generating specificity, and a short 
linker connecting these two elements, which fits in the cata-
lytic pocket. The zinc-binding groups can be a carboxylic 
acid in valproic acid (VPA), a hydroxamic acid in Vorinostat, 
benzamide in Entinostat, sulfhydryl in Romidepsin,30 and a 
ketone in Trapoxin. The linkers can be simple carbon chains, 
like in Vorinostat, or aromatic groups, like in Entinostat. 
HDACi in clinical trials are reported in Figure 3. Trichos-
tatine (TSA) from Streptomyces hygroscopius was isolated 
as an antifungal antibiotic and was incidentally shown to 
have an anti-proliferative activity on murine leukemia cells. 
Further studies demonstrated that it was a pan-HDACi. The 
hydroxamate portion at the end of the molecule acts as a 
zinc-binding group. Because of toxic side effects, it is not 
used clinically but participates in the rational conception of 
HDACi via molecular modeling, as shown in Figure 2.
Besides its HDAC inhibition activity, Vorinostat   (Figure 2, 
left), deriving from TSA, has a complex and not yet fully char-
acterized activity leading to the accumulation of acetylated 
histones and non histone proteins. First generation HDACi 
are not selective except for a partial selectivity achieved31,32 
in rare cases using bulk chemical groups to generate specific 
interactions with the external surface of the active site of the 
enzyme, like in tubacin.33 Sulfur-based zinc-binding groups 
also showed some selectivity in compounds like Largazole, 
a potent and selective HDACi for HDAC1 and 2. It is a 
densely functionalized macrocyclic peptide   isolated from the 
Cyanobacterium symploca sp. by Luesch and coworkers.34 
Entinostat and Mocetinostat have selectivity for HDAC1-3 
and also against HDAC11 for the latter. Valproate and 
sodium butyrate (NaB) better target HDAC I and IIa. For 
sirtuins35 inhibition is based on NAD+ competitive binding 
with attempts to propose a pharmacophore, according to the 
various inhibitor structures described.36
SIRT1 activation is the novel therapeutic approach to treat 
chronic inflammatory diseases, and enzyme activators are 
therefore sought. Many screening tests to search for HDACi 
use short histone peptides, capturing baits and engineered 
cells. All have their limitations because, in vivo, HDAC are 
parts of mega Daltons modeling chromatin complexes that 
may change within each cell type.
HDAC inhibitors metabolism
The metabolism of HDACi is an important concern during 
clinical assays. It is studied to determine the correlation 
between HDACi blood concentration, effective biological 
effects and eventual drug interactions. The known metabo-
lisms of some HDACi are reported in Figure 4. TSA is 
metabolized as the inactive trichostatic acid, which is fur-
ther demethylated37 for rapid clearance (Figure 4). Phenyl 
butyrate (PB) metabolism has been described in several 
contexts.38 PB is β-oxidized to phenylacetate, and cleared 
out upon glutamine addition. Vorinostat is also oxidized 
to 4-anilino-4-oxobutanoic acid and glucuronylated.39,40 
Romidepsin is a disulfide prodrug. The real active form cor-
responds to the free thiol metabolite,41 produced in vivo; the 
butenthiol part being thought to be the zinc-binding group. 
A glutathione conjugate has also been described,42 which is 
metabolized in vivo by the cytochrome P450s43 with slow 
and high acetylating subjects. Other HDACi stabilities have 
been investigated.44,45
in-vitro effects of HDAC inhibitors
DNA chips studied the transcriptome of cells treated with 
Vorinostat and Romidepsin,46 revealing that the expression 
of 40% of all genes was affected over a period of 16 hours. 
A Belinostat mRNA signature of 25 genes was sufficient to 
assess the overall gene modulation. Panobinostat modulated 
cell cycles and angiogenic genes.47 Tumor antigen expression 
modulation and major histo-compatibility antigen (MHC) 
molecule induction48 have been observed with Dacinostat.49 
Mice bearing human tumor xenografts treated with Belinostat 
showed a modulation of the expression of genes active in 
the cellular G2/M phase. This was different from what was 
seen with 5-fluorouracil (5-FU), Cisplatin, Paclitaxel, or 
Figure 2 Left panel: X-ray crystallographic data for SAHA bound to HDAC8. The 
zinc atom in the HDAC active site is shown in grey. The hydroxamic acid group in 
SAHA is bound to Zn2+, the phenylamide group is outside the enzyme active site, and 
these two elements are linked by a short carbon chain. Right panel: Modeled tubulin 
bound to HDAC6. Zn2+ in the active site is shown in grey. The hydroxamic acid group 
in tubulin is bound to the Zn2+, the phenylamide group is outside the enzyme active 
site and these two elements are linked by a short carbon chain. A bulk chemical entity 
has been grafted onto the phenylamide part of SAHA to obtain selectivity towards 
HDAC6 due to specific S-pi interactions from sulfur atom (in yellow). 
Abbreviations: HDAC, histone deacetylase; SAHA, suberoylanilide hydroxamicacid.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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JNJ-26481585
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Hydroxamic acids
Belinostat,
PDX101 
Givinostat,
ITF2357
Valproic acid,
VPA
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FK228, 
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FR901228
Isostax
Panobinostat,
LBH589
Dacinostat,
NVPLAQ824
Tacedinaline,
CI-994
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MS-275, 
SNX-275
Phenylbutyrate, PB
Sodium butyrate,
NaB
Short chain carboxylic acids
Benzamides
Vorinostat,
SAHA, 
Zolinza®
Cyclic peptides
Mocetinostat,
MGCD0103
Pivanex, AN-9, 
Pivaloyloxymethyl, 
butyrate
PCI-24781,
cra-024781
VPA Mg salt
Phenylacetate, PA
Trichostatin A,
TSA 
Figure 3 Histone deacetylase (HDAC) inhibitors used in clinical trials arranged by chemical classes.
Thiotepa. Synergistic effects were obtained when combining 
HDACi and DNA demethylating agents,50 or HDACi and 
all-trans retinoic acid (ATRA), a cell-differentiating agent 
used to treat acute promyelocytic leukemia (APL).51 The 
influence of epigenetic modulators to modify stem cell fate 
and its relevance for curing diseases has been reviewed.52 
Successful therapeutic use of HDACi may thus depend on 
the cellular environment, the specific HDAC targeted, and 
the relative dependence of the tumor on the unique set of 
pathways influenced by a specific HDAC. Results are sum-
marized in Table 1.53
Clinical trials with zinc-dependent HDACi
This part of the review describes the HDACi that have 
been or are being investigated in clinical trials. In Table 2, 
all current trials are recapitulated. In Table 3, and for each 
molecule, some data related to epigenetic measurements are 
summarized.
PB or its sodium salt
PB or its corresponding sodium salt (NaPB) is a short chain 
fatty acid approved by the Food and Drug Administration 
(FDA) for the treatment of hyperammonemia. It stops the Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Figure 4 Metabolic processes for some histone deacetylase inhibitors. 
Abbreviations: PB, phenyl butyrate; TSA, trichostatin.
cell cycle in its G1–G0 phase. PB is an efficient HDACi 
at about 0.5 mM.54,55 PB induces apoptosis – probably via 
c-jun N-terminal kinase (JNK) – in lung carcinoma cells,56 
p21waf1-mediated growth arrest in MCF-7 cells,57 tumor 
necrosis factor (TNF)-α58 or peroxisome proliferator-activated 
receptor (PPAR)γ-mediated59 cell differentiation, and is more 
potent than phenylacetate in prostate cancer cells,60 while 
increasing MHC class I expression. PB is converted in vivo 
into the active metabolite phenylacetate (PA) by β-oxidation 
in the liver and kidney mitochondria.61 Most dose-limiting 
toxicities (DLTs) are fatigue, nausea, and somnolence. 
Preliminary studies have been conducted in patients with 
recurrent glioblastoma multiform (GBM)62 (Table 3, A). 
Phase I studies have been conducted in patients with hormone 
refractory prostate cancers,63 refractory solid tumor malig-
nancies64 like colon carcinoma, non small cell lung cancer 
(NSCLC), anaplastic astrocytoma, GBM, bladder carcinoma, 
sarcoma, ovarian carcinoma, rectal hemangiopericytoma, and 
pancreatic carcinoma,65 mainly as intravenous infusions but 
also in AML and myelodysplastic syndrome (MDS).66 DLTs 
were neuro-cortical with milder fatigue and nausea/vomiting, 
light-headedness, short-term memory loss, sedation, confu-
sion, and hypocalcemia. Although central nervous system 
(CNS) toxicity was observed, infusions were well tolerated 
(Table 3, B). The active metabolite PA accumulated.
In the AML/MDS study,67 with sequential administration 
of 5-aza-cytidine (5-aza) (Table 3, C), partial remissions or 
stable diseases were obtained. Targeting different biologi-
cal mechanisms is feasible with acceptable toxicity. Phase I 
trials in combination with several drugs have been reported. 
Prostate, colorectal, leiomyosarcoma, and esophageal can-
cers were treated in combination with 5-aza (Table 3, C),68 
  metastatic colorectal cancer with fluorouracil 5-FU as a 
24-hour continuous intravenous infusion (CIV).69 With 5-aza, 
no re-expression of E-cadherin, endothelin B, and glutathione 
S transferase (GST) pi was observed, a result explained by 
the lack of dose effect or by the fact that DNA methylation 
is an S-phase-dependent process while in-vivo prostatic cells 
may be in S-phase at any given time. Stable disease was the 
best response. Combining 5-FU appeared also feasible.
Pivaloyloxymethyl butyrate
Pivaloyloxymethyl butyrate (AN)-9, is an ester prodrug of 
butyric acid (BA)70 but with a greater potency at inducing 
malignant cell differentiation and tumor growth inhibition. 
It showed more favorable toxicological,   pharmacological, Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Table 1 in-vitro modulation of gene expression by HDACi
HDACi  Gene expression
Upregulated (cell type) Downregulated (cell type)
vorinostat  
Romidepsin
TOB1, BTG1, BTG2, MX11, MAD, MLX, TieG, iD2, iD3, 
CDKs, DRAK1, DRAK2, DAPK3, GADD45β, GADD153.
MYC, MCM-3, MCM-5, MCM-7.
vorinostat (in CDK2 
expressing cells)
PKCA, PAK1, TRAF1. ZAK, BCL2, B-MYC, GRiM19, PDC4, P2RX1, 
CD27.
Belinostat CTGF, DHRS2, DNAJB1, H1F0, MAP1 LC3B, ODC, SAT, 
TACC1.
ABL1, CTPS, eiF4G2, KPNB1, CAD, RAN, TP53, 
TYMS, TD-60.
Panobinostat p-FLT-3, FLT-3, Bcr-Abl, p-AKT, phospho-eRK1/2. 
TS (in HCT116 cells).
Apicidin CDKN1A, gelsolin.
Abbreviations: TOB1, transducer of eRBB2; BTG1, B-cell translocation gene 1; BTG2, B-cell translocation gene 2; MX11, MAX dimerization protein 1; MAD, mitotic arrest 
deficient-like; MLX, MAX-like protein X; TIEG, Kruppel-like factor 10; ID2, inhibitor of DNA binding 2; ID3, inhibitor of DNA binding 3; CDKs, cyclin-dependent kinase; 
DRAK1, serine/threonine kinase; DRAK2, serine/threonine kinase 17b; DAPK3, death-associated protein kinase 3; GADD45β, growth arrest and DNA-damage-inducible 
45 beta; GADD153, DNA-damage-inducible transcript 3; MYC, v-myc myelocytomatosis viral oncogene homolog tumor necrosis factor; MCM-3-7, minichromosome 
maintenance complex component 3-5-7; PRKCA, Protein kinase C a; PAK1, p21 protein (Cdc42/Rac)-activated kinase 1; TRAF1, TNF receptor-associated factor 1; ZAK, 
zinc finger protein 33A; BCL2, B-cell CLL/lymphoma 2; B-MYC, c-myc binding protein; GRIM19, NADH dehydrogenase 1 alpha subcomplex; PDC4, DEP domain containing 
4; P2RX1, purinergic receptor; P2X, ligand-gated ion channel1; D27, CD27 molecule; CTGF, connective tissue growth factor; DHRS2, dehydrogenase/reductase S2; DNAJB1, 
DnaJ (Hsp40) homolog; subfamily B; member 1; H1F0, H1 histone family; member 0; MAP1LC3B, microtubule-associated protein 1 light chain 3 beta; ODC, ornithine 
decarboxylase 1; SAT, spermidine/spermine N1-acetyltransferase 1; TACC1, transforming acidic coiled-coil containing protein 1; ABL1, c-abl oncogene 1; CTPS, CTP 
synthase; eiF4G2, eukaryotic translation initiation factor 4 gamma; KPNB1, karyopherin beta; CAD, carbamoyl-phosphate synthetase 2; RAN, member RAS oncogene family; 
TP53, tumor protein p53; TYMS, thymidylate synthetase; TD-60, regulator of chromosome condensation 2; FLT-3, fms-related tyrosine kinase 3; Bcr-Abl, c-abl oncogene 1; 
non-receptor tyrosine kinase; p-AKT, v-akt murine thymoma viral oncogene homolog 1; TS, Thymidilate synthase; CDKN1A, cyclin-dependent kinase inhibitor 1A; CDK2, 
cyclin-dependent kinase inhibitor 2A.
and pharmaceutical properties than BA in preclinical   studies. 
BA itself induces p16 expression and growth arrest of colon 
cancer cells,71 and modifies caspase distribution during 
apoptosis.72 AN-9 down regulates c-jun and c-myc and 
induces differentiation in leukemia cells.73 It is decomposed 
by esterases in vivo to yield butyric and pivaloyl acids and 
a formaldehyde molecule, responsible for toxicity resulting 
in visual acuity disorders. It has demonstrated a synergistic 
effect with other anticancer agents by reducing bcl-2 levels.74 
Initial study75 with I.V . of AN-9 in advanced solid malignan-
cies (Table 3, E) gave partial responses, and stable diseases as 
best responses. Later, a multicenter trial of pivaloyloxymethyl 
butyrate76 in refractory NSCLC (Table 3, F), administered as 
a continuous I.V . infusion, gave partial responses.
vPA
VPA is a nontoxic short-chain carboxylic acid used for the 
treatment of epilepsy with a long clinical history and well 
known pharmacokinetics (PKs) and pharmacodynamics 
(PDs).77,78 VPA induces chromatin decondensation,79 and dif-
ferentiation in neural progenitor cells,80 and inhibits HDAC 
activity81 in the mM range (preferentially HDAC1, 2).82 The 
antiproliferative activity was associated with aberrant cyclin 
D3 functionality during the C6 glioma G1 phase.83 Acti-
vation of PPARδ was present in F9 cells.84 VPA induces 
caspase-dependent and -independent apoptosis in leukemia 
cells,85 and in AML cells expressing P-gp and multidrug 
resistance protein 1 (MRP1),86 inhibits production of TNF-α 
and   interleukin (IL)-6 and activates nuclear factor kappa B 
(NF-κB).87 VPA has been evaluated in combination with 
other anticancer compounds. For AML, increased 5-aza 
cytotoxicity was associated to cyclin D1 and p27(Kip1) 
expression,88 while sequential VPA/ATRA treatment 
reprograms differentiation.89 VPA induces p16INK4A 
upregulation and apoptosis and sensitizes melanoma cells 
to chemotherapy.90 Interestingly, most of the clinical trials 
reported are for combination therapies.
A Phase I was conducted91 for refractory advanced cancer 
(colorectal, melanoma, NSCLC, and others) (Table 3, G). 
VPA/ATRA combination was evaluated for several diseases. 
Poor risk AML92 (Table 3, H), MDS and relapsed or refrac-
tory AML93 (Table 3, I) have also been investigated. A 52% 
response rate was observed in MDS patients. ATRA exerted 
no additional effect in patients receiving the combination, 
but could be used to induce a second response in relapsing 
VPA-treated patients. In recurrent or refractory AML or MDS 
in a Phase II protocol94 (Table 3, J), ATRA was administered 
when VPA reached the target serum concentration. The 
differentiation therapy with VPA was effective in 30% of 
patients. In 11 elderly patients, de novo AML95 (Table 3, K) 
was also treated with theophyllin to increase cAMP levels and 
major cell differentiation.96 Complete marrow response was 
observed in three patients, including one complete   remission. 
Two additional patients had hematologic improvement. 
Patients with AML-M6 were found   particularly97 respon-
sive, probably due to T-cell acute lymphocytic   leukemia 1 Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Table 2 Clinical trials for epigenetic drugs
Safety study of CHR-3996, in patients with advanced solid tumours
Safety and Tolerability of CHR-2845 to treat hematological diseases or lymphoid malignancies
A safety and dose-finding study of JNJ-26481585 for patients with advanced refractory leukemia or myelodysplastic syndrome
Phase ii study of Givinostat in very high-risk relapsed/refractory Hodgkin’s lymphoma patients
Phase ii study of Givinostat followed by Mechlorethamine in relapsed/refractory Hodgkin’s lymphoma patients
Phase ii study of Givinostat in refractory/relapsed lymphocytic leukemia
Phase ii study of Givinostat in combination with hydroxyurea in polycythemia vera
Clinical trial of Belinostat in patients with advanced multiple myeloma
Belinostat to treat tumors of the thymus at an advanced stage
Belinostat in relapsed or refractory peripheral T-cell lymphoma
Belinostat in treating patients with MSD
Safety and efficacy of Belinostat when used with standard of care chemotherapy for untreated NSCLC
A Phase i study of Belinostat in combination with Cisplatin and etoposide in adults with SCLC and other advanced cancers
vorinostat for locally advanced NSCLC
vorinostat in treating patients with metastatic and/or locally advanced or locally recurrent thyroid cancer
A Study of the efficacy of Vorinostat in patients with polycythemia verae and essential thrombocythemia
Study of vorinostat Plus Capecitabine and Cisplatin for 1st Line Treatment of metastatic or recurrent gastric cancer
vorinostat with Capecitabine Using a new weekly dose regimen for advanced breast cancer
Study of vorinostat combination with Bortezomib in patients with multiple myeloma
Study of Vorinostat and Gefitinib in relapsed/or refractory patients with advanced NSCLC
Proteasome inhibitor NPi-0052 (marizomlib, salinosporamide A) and vorinostat in patients with NSCLC, pancreatic cancer, melanoma or lymphoma
vorinostat combined with Gemtuzumab Ozogamicin, idarubicin and Cytarabine in acute myeloid leukemia
Trial for locally advanced Her2 positive breast cancer using vorinostat and Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a weekly basis
Sirolimus and vorinostat in advanced cancer
Temsirolimus and vorinostat in treating patients with metastatic prostate cancer
vorinostat, Carboplatin and Gemcitabine plus vorinostat maintenance in women with recurrent, Platinum-sensitive epithelial ovarian, Fallopian tube, 
or peritoneal cancer
vorinostat and Gemcitabine in treating patients with metastatic or unresectable solid tumors
vorinostat and Lenalidomide in treating patients with relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma
Hydroxychloroquine + vorinostat in advanced solid tumors
vorinostat in combination with palliative radiotherapy for patients with NSCLC
vorinostat in combination with radiation therapy and infusional Fluorouracil (5-FU) in patients with locally advanced adenocarcinoma of the pancreas
Study of 5-azacytidine in combination with vorinostat in patients with relapsed or refractory diffuse large B cell lymphoma
An investigational Study of vorinostat Plus Targretin (Bexaroten) in cutaneous T-cell lymphoma patients
Phase ii Trial of vorinostat and Tamoxifen for patients with breast cancer
Oral Panobinostat in relapsed or refractory CLL and MCL (non-Hodgkin’s lymphoma)
Panobinostat in Phase ii in SCLC
Panobinostat in treating patients with relapsed or refractory acute lymphoblastic leukemia or acute myeloid leukemia
Study of Oral Panobinostat in adult patients with refractory/resistant cutaneous T-cell lymphoma
Study of Bortezomib and Panobinostat in treating patients with relapsed/refractory peripheral T-cell lymphoma or NK/T-cell Lymphoma
Study of Panobinostat to treat malignant brain tumors
Study of Oral Panobinostat in patients with cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma
Panobinostat in adult patients with advanced solid tumors or cutaneous T-cell lymphoma
A study of Panobinostat as second-line therapy in patients with chronic graft-versus-host disease
Panobinostat treatment for refractory clear cell renal carcinoma
A Study to investigate the effect of food on oral Panobinostat absorption in patients with advanced solid tumors
eRB-B4 after treatment with Panobinostat in eR+ Tamoxifen refractory breast cancer
Panobinostat in addition to corticosteroids in patients with acute graft versus host disease
Panobinostat and imatinib Mesylate in treating patients with previously treated chronic phase chronic myelogenous leukemia
Study of imatinib, a Platelet-derived Growth Factor Receptor inhibitor, and Panobinostat, in the treatment of newly diagnosed and recurrent chordoma
Oral Panobinostat in combination with Carboplatin and Paclitaxel in advanced solid tumors
Safety and efficacy studies of Panobinostat and Bicalutamide in patients with recurrent prostate cancer after castration
Panobinostat and everolimus in treating patients with recurrent multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma
Panobinostat and Fluorouracil followed by Leucovorin Calcium in treating patients with stage iv colorectal cancer who did not respond to previous 
Fluorouracil-based chemotherapy
Sorafenib and Panobinostat in hepatocellular carcinoma
A Safety study of Panobinostat and everolimus to stabilize kidney cancer
Phase i/ii Study of Panobinostat and erlotinib for advanced aerodigestive tract cancers 
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Table 2 (Continued)
Use of Panobinostat with or without Rituximab to treat B-cell non-Hodgkin lymphoma
entinostat in treating patients with advanced solid tumors or lymphoma
entinostat in treating patients with hematologic cancer
Safety and efficacy study of Entinostat a new chemotherapy agent to treat metastatic melanoma
entinostat and Sorafenib Tosylate in treating patients with advanced or metastatic solid tumors or refractory or relapsed acute myeloid leukemia
entinostat and isotretinoin in treating patients with metastatic or advanced solid tumors or lymphoma
entinostat and Azacitidine in treating patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia
entinostat and Clofarabine in treating patients with newly diagnosed, relapsed, or refractory poor-risk acute lymphoblastic leukemia or bilineage/
biphenotypic leukemia
A Phase ii Study of entinostat, in combination with GM-CSF treating relapsed and refractory myeloid malignancies
Azacitidine with or without entinostat in treating patients with MSD, chronic myelomonocytic leukemia, or acute myeloid leukemia
interleukin 2, Aldesleukin and entinostat for kidney cancer
Safety and Efficiency Study of Valproic Acid In HAM/TSP
valproic Acid as an effective therapy for chronic lymphocytic leukemia
valproic Acid and its effects on Hiv latent reservoirs
valproic Acid in treating patients with previously treated non-Hodgkin lymphoma, Hodgkin lymphoma, or chronic lymphocytic Leukemia
Bevacizumab, chemotherapy and valproic Acid in advanced sarcoma
Combined therapy with valproic Acid, All-trans Retinoic Acid (ATRA) and Cytarabine in acute myelogenous leukemia
valproic Acid with Temozolomide and radiation therapy to treat brain tumors
Azacytidine and valproic Acid in patients with advanced cancers
Phase ii study of 5-Azacytidine Plus valproic Acid and eventually ATRA in intermediate ii and high risk MDS
Phase i/ii Trial of valproic Acid and Karenitecin for melanoma
5-azacytidine, valproic Acid and ATRA in acute myeloid leukemia and high risk MDS
Hydralazine and valproate added to chemotherapy for breast cancer
Hydralazine and valproate plus Cisplatin chemoradiation in cervical cancer
A Pilot study of Pivanex in patients with chronic lymphocytic leukemia
A Pilot study of Pivanex in patients with malignant melanoma
Comparative trial of Pivanex and Docetaxel vs Docetaxel Monotherapy in Patients with advanced NSCLC
Study of SB939 in Subjects with myelofibrosis
SB939 in treating patients with locally advanced or metastatic solid tumors
SB939 in treating patients with recurrent or metastatic prostate cancer
Phase 2 study of Azacitidine vs MGCD0103 vs combination in elderly subjects with newly diagnosed AML or MDS
AR-42 (OSU-HDAC42) in treating patients with advanced or relapsed multiple myeloma, chronic lymphocytic leukemia, or Lymphoma
Resminostat in relapsed or refractory Hodgkin’s lymphoma
Study of the safety and tolerability of PCi-2478 in patients with lymphoma
Safety and tolerability study of PCi-24781 in subjects with cancer
Phase i Study of gene induction mediated by sequential Decitabine/Depsipeptide infusion with or without concurrent Celecoxib in subjects with 
pulmonary and pleural malignancies
Romidepsin in treating patients with relapsed or refractory non-Hodgkin’s Lymphoma
Data from US National Cancer institute
(TAL1)98 and GATA199 interactions with HDACi, inducing 
differentiation in murine erythroleukemia (MEL) cells. 
Siitonen et al100 reported a negative study trying VPA, in 
combination with 13-cis-retinoic acid (13-cis-RA)101 and 
1,25-dihydroxyvitamin D3, in 19 naive patients with MDS 
or chronic myelomonocytic leukemia (CMML) (Table 3, L). 
Combinations with demethylating agents have been reported. 
Phase I/II102 study with 5-aza-2′-deoxycytidine (5-azaDc) in 
leukemia (Table 3, M) included gene expression analysis 
(p57kip2, p15, p73, MDR1 and THBS2). Initial DNMT1 
levels were too low to be informative. A Phase I study103 
with 5-azaDc in AML (Table 3, N) gave partial to complete 
remissions, warranting further studies of 5-azaDc alone or 
with alternative HDACi. A Phase I104 study of epigenetic 
modulation with 5-aza for advanced cancers (Table 3, O, 
colon, skin melanoma, breast, other) gave stable diseases. 
A Phase I/II study105 with 5-aza and ATRA for AML and 
MDS (Table 3, P) gave 42% positive overall responses.
Other combinations were investigated: a Phase I dose 
escalation combination trial with epirubicin, 5-FU, and 
cyclophosphamide106 in breast cancer (Table 3, Q), and a 
Phase I trial107 with epirubicin for solid tumors (Table 3, R). 
The rationale for the combination was to facilitate epirubicin 
access to DNA to potentiate its strand breaks activity as a 
topoisomerase II inhibitor. Intrinsic epirubicin toxicity was 
not exacerbated. Reverse combination was found inadequate 
by the same group. The same group investigated combina-
tion with the topoisomerase I inhibitor karenitecin (KTN) Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Table 3 in vivo HDACi effects from clinical data
HDACi (metabolism,  
half-life, bioavailability)  
and combinations
MTD, cancer target, DLTs Biological analyses  
(source)
Remarks or  
recommendations
PB converted in vivo to the  
active metabolite PA, not  
indicated, 78% at 0.5 mM
A
B
Phase ii, 27 g/day, GBM,  
common DLTs
300–410 mg/kg/day, various  
cancers, CNS
Contradictory  
with P450-inducing  
anticonvulsants.  
One complete 
response for 5 years
PB+5-aza C AML/MDS, skin reaction  
(5-aza)
H4 acetylation increased  
(not correlated with response)
D 25 mg/m2/d SQ d. 1–14, Several  
cancers, common DLTs +  
confusion, hearing loss,  
triglyceridemia and hyperuricema
Low DNMT activity
AN-9  
is converted in vivo to  
the active metabolite BA,  
half-life ,2 minutes
e 3.3 g/m2/day for the solubility  
limits, advanced solid malignancies,  
common DLTs + visual complaintsa
F Phase ii refractory NSCLC,  
common DLTs and dysgeusia
well tolerated, active  
alone and usable  
for NSCLC with  
chemotherapy, 1-year 
survival around 30%
vPA  
Glucuronylation, glutamination, 
half-life: 9–18 hours
G 60 mg/kg/d, refractory advanced  
cancer, neurological side effects  
(Grade 3/4)
H3, H4 acetylation increased,  
HDAC2 decreased (PMBC)
vPA+ATRA H AML, neurologic and cardiovascular  
toxicity
HDAC2 decreased (PMBC)
i MDS and relapsed or refractory AML Bone marrow blast count  
correlated with response
vPA should be used  
alone for low risk  
MDS and with other  
chemotherapeutics  
for high risk MDS
J Recurrent or refractory AML or  
MDS, neurocortical, severe bone  
pain (Grade 3/4)
No significant blast count  
reduction, cytogenetic  
analysis of patients  
is described
Platelet transfusion  
independence should  
reduce palliative care  
and improve the  
quality of life
K AML Particular response  
from patients with  
AML-M6
vPA+13-cis RA or  
vitamin D3
L MDS or CMML No relation between vPA  
serum level, H3 acetylation  
(PMBC, BMMC) or clinical  
response
Near 50% patients  
had to end the  
treatment
vPA + 5-azaDc M Phase i//ii leukemia DNA demethylation decreased,  
H3 and H4 acetylation  
increased, p15 reactivation,  
p21 cip1 not stimulated
Objective responses  
rate: 22%, complete  
remissions: 19%,  
safety and efficacy  
correlated with  
reversal of epigenetics  
marks
N AML, limited non hematologic  
toxicity (5-azaDc), encephalopathy  
(vPA)
Correlation with re-expression  
of eR mRNA and clinical  
response, p15 promoter  
methylation decreased DNA 
methylation decreased, DNMT1  
decreased, histone acetylation 
increased
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Table 3 (Continued)
HDACi (metabolism,  
half-life, bioavailability)  
and combinations
MTD, cancer target, DLTs Biological analyses  
(source)
Remarks or  
recommendations
vPA + 5-aza O Advanced cancers DNA methylation decreased  
(not significant), H3 acetylation  
increased (PMBC)
Safe at doses up to  
75 mg/m2 for 5-aza
vPA + 5-aza + ATRA P 50 mg/kg/d for 7 days, AML and  
MDS, neurotoxicity
DNA methylation decreased,  
H3 and H4 deacetylation  
increased, p21 cip1 and  
p15 mRNA expression not  
associated with clinical  
response
Combination safe  
with significant  
clinical activity
vPA + epirubicin  
or 5-FU or  
cyclophosphamide
Q Breast cancers H3 and H4 acetylation  
increased (PMBC), strong  
correlation for HDAC2  
decreased in MCF-7 cells, no  
correlation for HDAC6
Objective responses  
for 64% (9/15) of the  
patients
vPA + epirubicin R Solid tumors, confusion,  
hallucinations, hearing loss and  
dizziness (due to vPA half-life)
48 hours exposure vPA for  
chromatin decondensation  
prior to epirubicin exposure.  
Histone acetylation increased  
(PBMN)
Responses were  
obtained for  
anthracycline-resistant 
cancers (breast,  
cervical and NSCLC).
vPA + KTN S Melanoma, no vPA/KTN synergistic  
toxicity
H3 and H4 acetylation  
increased (PMBC, apparent  
plateau for 60 mg/kg/day vPA)
Potential use in  
randomized trials  
where topoisomerase i 
inhibitors are  
involved
vPA + dazacarbine +  
interferon-α
T Advanced inoperable or metastatic  
melanoma, high doses vPA  
side effects
Histone acetylation increased  
(PMBC) with adjusted vPA  
doses.
Modification of  
the schedule for  
further evaluation of  
vPA with chemo- 
immunotherapy
vPA Mg salt U Cervical cancer, depressed level of  
consciousness
H3 and H4 acetylation  
increased (PMBC and tumors).
vPA Mg salt + hydralazine v Chemotherapy resistant refractory  
solid tumors, hematologic toxicity
DNA methylation decreased,  
histone deacetylase activity  
decreased, promoter  
methylation decreased for  
RAR-α and DPK. 1091 genes  
upregulated, 89 genes  
downregulated.
Patients from  
cisplatin, carboplatin,  
paclitaxel, vinorelbine,  
gemcitabine,  
pemetrexed,  
topotecan,  
doxorubicin,  
cyclophosphamide,  
and anastrozole  
treatments.  
Supports epigenetic- 
driven tumor-cell  
chemoresistance  
hypothesis.
vorinostat, glucuronylated,  
β-oxidized, half-life ,2 hours,  
43% oral bioavailability
w Solid tumors and hematological  
malignancies, leukcopenia,  
thrombocytopenia, respiratory  
distress (Grade 3/4)
Histones acetylation  
increased (v)
X Mesothelioma, commonb DLTs. A randomized Phase iii 
study can be  
proposed for patients  
already treated  
unsuccessfully with  
pemetrexed
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Table 3 (Continued)
HDACi (metabolism,  
half-life, bioavailability)  
and combinations
MTD, cancer target, DLTs Biological analyses  
(source)
Remarks or  
recommendations
Y Hematologic malignancies and solid,  
common DLTs + anorexia
Histone acetylation (PMBC, 200 to 
600 mg).
Safe when  
administered  
chronically, broad  
range of antitumor  
activity.
Z Advanced leukemias and MDS (AML,  
CLL, MDS, ALL, CML), common  
DLTs (Grade 3/4)
incomplete blood count  
recovery (AML), histone  
acetylation increased at  
all doses
None of the  
responding patients  
have a specific  
mRNA signature for  
antioxidant genes  
to be used as a  
biomarker for further  
studies.
AA Recurrent or persistent epithelial  
ovarian or primary peritoneal  
carcinoma platinum-resistant/ 
refractory, common Grade 3 
DLTs + leucopoenia and  
neutropenia (Grade 4).
SAHA is well  
tolerated but had  
minimal activity as a  
single agent
AB Measurable, relapsed or refractory  
breast cancer or NSCLC or  
colorectal cancer, common DLTs  
(300–400 mg) No DLTs at 200 mg.
The limited patient  
exposure was not  
sufficient to assess  
SAHA efficacy.
AC Recurrent and/or metastatic head  
and neck tumors, thrombocytopenia,  
anorexia, and dehydration
AD GBM, nonhematologic, and  
hematologic toxicities (Grade 3).
H2B, H4 and H3 acetylation  
increased. Upregulation of  
e-cadherin.
enzyme-inducing  
anticonvulsants  
gave lower SAHA  
concentrations, well  
tolerated, modest  
activity.
Ae Metastatic radioiodine-refractory  
thyroid carcinoma, common DLTs  
(Grade 3), pneumonia, severe  
thrombocytopenia
Tg (DTC) and calcitonin (MTC) 
are not convenient biomarkers.
Lack of therapeutic  
effect
vorinostat + carboplatin  
and paclitaxel
AF Advanced solid malignancies,  
common DLTs + emesis (Grade 3),  
neutropenia (Grade 4)
SAHA metabolite 4-anilino- 
4-oxobutanoic acid used  
as a marker to monitor for  
adherence to SAHA therapy.
Combinations  
well tolerated and  
increased SAHA half- 
life, paclitaxel PKs not 
altered
Belinostat, half-life  
1–2 hours
AG 1000 mg/m2/day, refractory solid  
tumors, common DLTs + atrial  
fibrillation
H4 acetylation (PMBC), iL-6  
expression levels proposed as  
a marker for HDACi toxicity209
50% of the patients  
achieve stable disease
AH 1000 mg/m2/day, heavily pre-treated  
patients with advanced hematological  
neoplasia, common DLTs
Histone acetylation increased  
(PMBC) up to 24 hours post  
injection.
No bone marrow  
toxicity as a  
parameter for  
combination  
therapies.
Ai Relapsed malignant pleural  
mesothelioma, common DLTs
No objective  
responses. One  
death from cardiac  
arrhythmia, possibly  
related to therapy.
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Table 3 (Continued)
HDACi (metabolism,  
half-life, bioavailability)  
and combinations
MTD, cancer target, DLTs Biological analyses  
(source)
Remarks or  
recommendations
AJ Resistant micro papillary ovarian  
tumors (LMP) and epithelial ovarian  
cancer, common DLTs + thrombosis  
(Grade 3)
H3 and H4 acetylation  
increased (PMBC and tumor  
tissue). Disease.
Diseases with poor  
prognostic and  
scarce studies, well  
tolerated, promising  
results for LMP
Givinostat AK Relapsed/refractory HL,  
thrombocytopenia and prolongation  
of QTc interval
QTc interval in some cases  
prompting drug discontinuation
Givinostat, alone or +  
dexamethasone
AL Twice daily 100 mg/4 days/week,  
12 weeks, MM, one death, cardiac  
toxicities (givinostat)
Already treated patients, one  
death was reported
Unlikely to play  
a significant role  
for MM, other  
combination may be  
investigated
Givinostat +  
meclorethamine
AM Relapsed/refractory HL TARC decrease in serum as  
an easy-to-detect biomarker  
predicting response to therapy, 
five (15%) complete remissions  
and eight (23%) partial  
remissions, median survival  
28 months, projected 2-year  
survival 52%
15% complete  
remissions, median  
survival at 28 months, 
projected 2-year  
survival of 52%.
Panobinostat, half-life  
11–16 hours
AN ,11.5 mg/m2, AML, ALL, MDS,  
common minor DLTs, and cardiac  
toxicity (Grade 3)
H3 acetylation increased  
(B-cells (CD19+) and blasts  
(CD34+)), H2B acetylation  
increased (CD19+ and CD34+  
cells), apoptosis increased for  
CD34+.
AO CTCL, classical DLTs at 20 mg +  
thrombocytopenia, toxic at 30 mg
RNA profiling: 23 genes  
regulated in all patients. H3  
acetylation increased (PMBC  
and tumors)
Complete remission
Panobinostat + docetaxel AP Castration resistant prostate  
cancer, neutropenia and dyspnea  
(Grade 3)
Progressive disease despite  
histone acetylation increased  
(PMBC) in first regimen, PSA  
decreased in second regimen
intravenous  
administration  
suggested for further  
investigations
Dacinostat, half-life  
9–18 hours
AQ Advanced solid tumors, common  
DLTs and transaminitis, fibrillation,  
raised serum creatinine, and  
hyperbilirubinemia.
Histones acetylation increased  
(PMBC), HSP90210 inhibition  
measured by HSP72 levels  
increased; H3 and H4  
acetylation increased for  
.24 hours, Hsp70 increased  
and c-Raf decreased.
Nonhistone-mediated  
effects requires  
further study
AR ALL, AML, CLL, CML, MDS, dose  
dependant DLTs: cerebral bleed  
secondary to thrombocytopenia  
(CLL), reversible hyperbilirubinemia
Histone acetylation increased  
.24 hours, nonlinear PK
Rematologic  
improvement  
observed, mean  
terminal half-lives  
9–18 hours (maximum 
plasma concentrations  
1.5 hours after the  
beginning of infusion).
PCi-24781 half-life  
5.9 hours, oral  
bioavailability 34%
AS Refractory advanced solid tumors,  
common and cardiac DLTs
Acetylation levels increased at  
1.5 hours post dose sustained  
$24 hours (oral).
(Continued)Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
130
Martinet and Bertrand
Table 3 (Continued)
HDACi (metabolism,  
half-life, bioavailability)  
and combinations
MTD, cancer target, DLTs Biological analyses  
(source)
Remarks or  
recommendations
entinostat, half-life  
34–50 hours,  
highly protein bound,  
apparent linear PKs
AT 10 mg/m2, advanced solid tumors  
or lymphoma, common DLTs
HDAC inhibition (PMBC) More frequent  
dosing proposed  
for evaluation from  
linear PKs data,  
elimination half-life  
dose-independent  
clearance
AU Refractory solid tumors and human  
lymphoid malignancies, reversible  
DLTs (Grade 3, hypophosphatemia,  
hyponatremia, and hypoalbuminemia)
Protein acetylation increased  
(by multivariable flow  
cytometry in PMBC (T cells  
(most robust response), B cells, 
and monocytes))
well tolerated  
administered weekly  
with food
Av 8 mg/m2 weekly for 4 weeks every  
6 weeks, AML, infections and  
neurologic toxicity
Protein and histone H3/H4  
acetylation increased (PMBC,  
BMMC), p21 expression  
increased, and caspase-3  
activation (BMMC)
Detailed cytogenetic  
analysis performed  
on patients, inherent  
resistance to MS-275  
for advanced leukemia  
with complex  
karyotype
Aw Advanced solid malignancies and  
lymphomas, hypophosphatemia,  
and asthenia
High degree of interpatient  
variations in H3 and H4  
acetylation increased (PMBC)
AX Metastatic melanoma, toxicity  
mild to moderate
Patients with  
pretreated metastatic, 
melanoma, treatment  
well tolerated, no  
objective responses,  
median time-to- 
progression was  
51–56 days
Mocetinostat, half-life  
6.7–12.2 hours
AY 45 mg/m2/d, advanced solid tumors,  
rare common DLTs
H3 acetylation increased  
(PwBC, measured with  
the BOC-Lys(ε-Ac)-AMC  
fluorophore), IL-6 induction
interpatient variability 
improved with low  
pH beverages
AZ 60 mg/m2, AML, MDS, ALL, and  
CML, common DLTs (Grade 3)
Histone acetylation increased  
(PwBC, measured with  
the BOC-Lys(ε-Ac)-AMC  
fluorophore).
Three complete bone 
marrow response,  
cytogenetic analysis  
of patients not  
correlated with  
responses, safe and  
anti-leukemia activity  
for advanced leukemia
BA Advanced leukemias or MDS,  
common DLTs
HDAC inhibition (PMBC) Four patients with  
stable disease
Mocetinostat continued BB 85 mg dose exhibited meaningful  
activity, HL
TARC levels correlated with  
clinical response
Two complete 
responses (10%), six 
partial responses (29%)
BC FL, common Grade 3 DLTs +  
anorexia, thrombocytopenia,  
pericardial serious adverse event
No clear relationships  
with schedules,  
cardiac diseases,  
pathologies, and  
biomarkers such as  
HDAC activity.
Tacedinaline BD 8 mg/m2/day for 8 weeks, repeated  
after a 2-week drug-free interval,  
solid tumors, common DLTs +  
thrombocytopenia, anemia, mucositis
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Table 3 (Continued)
HDACi (metabolism,  
half-life, bioavailability)  
and combinations
MTD, cancer target, DLTs Biological analyses  
(source)
Remarks or  
recommendations
Tacedinaline + capecitabine Be 6 mg/m2 Tacedinaline and 2000  
mg/m2/day capecitabine, for 2 weeks  
of a 3-week cycle, advanced solid  
malignancy, DLT was  
thrombocytopenia
No overlapping  
toxicity
Tacedinaline + gemcitabine BF Advanced pancreatic cancers,  
neutropenia, and thrombocytopenia
Combination does not 
improve treatment
Depsipeptide, natural  
disulfide prodrug,  
half-life 8 hours
BG 13.3 mg/m2, incurable cancers,  
common DLTs + thrombocytopenia,  
and fatigue.
Histone acetylation increased  
(MNPB), PC3 cell cycle arrest  
induction, MDR-1 induced,  
functional PgP.
4-hour infusion safe
BH 17.8 mg/m2/4 h, advanced or  
refractory neoplasms, common  
DLTs + grade-4 thrombocytopenia  
and cardiac arrhythmia.
Histone acetylation increased  
(PMBC), MDR-1 induced.
Continuous cardiac  
monitoring, one  
partial response,  
472.6 ng/mL mean  
maximum plasma  
concentration at MTD
Bi CLL, AML, common DLTs HDAC inhibition increased,  
histone and p21 promoter  
H4 acetylation increased,  
p21 protein and 1D10  
antigen expression increased,  
acetylation increased for  
H4 K5, K12, K8, K16, and  
H3 K9, K14
BJ 17 mg/m2, refractory or recurrent  
solid tumors, reversible,  
asymptomatic T-wave inversions,  
transient asymptomatic sick sinus  
syndrome, and hypocalcemia
HDAC inhibition increased  
(PMBC)
Depsipeptide is well  
tolerated but no  
objective responses
BK MDS and AML, common DLTs  
(Grade 3/4 asymptomatic  
hypophosphatemia)
Apoptosis increased and  
changes in myeloid maturation  
marker expression. No changes 
in H3 and H4 acetylation,  
CD34/C13 stimulation.
One complete  
remission (AML)  
acceptable toxicity,  
limited activity in  
unselected AML/MDS  
patients
BL Refractory renal cell cancer,  
cardiac side effects
One complete  
response but not  
active enough in  
this population, one  
sudden death
BM Metastatic neuroendocrine tumors,  
common DLTs, serious cardiac  
adverse events
One sudden death
BN Lung cancers H4 acetylation increased, p21 
expression increased. 16 gene  
expressions stimulated $2-fold, 
.1000 genes repressed  
$2-fold.
Depsipeptide not  
appropriate but  
renormalize lung  
cancer cells to normal 
bronchial epithelia
Notes: aResulted from formaldehyde released after AN-9 metabolism; bCommon DLTs are considered to be fatigue, nausea, vomiting.
Abbreviaions: 5-aza, 5-aza-cytidine; 5-azaDc, 5-aza-2′-deoxycytidine; 5-FU, 5-fluorouracil; 13-cis-RA, 13-cis-retinoic acid; ALL, acute lymphoblastic leukemia; AMC, 7-amino-
4-methylcoumarin; AML, acute myeloid leukemia; AN-9, pivaloyloxymethyl butyrate 9; ATRA, all-trans retinoic acid; BA, butyric acid; BMMC, bone marrow mononuclear 
cell; CLL, chronic lymphocytic leukemia; CML, chronic myelocytic leukemia; CMML, chronic myelomonocytic leukemia; CNS, central nervous system; CTCL, cutaneous 
T-cell lymphoma; DLT, dose-limiting toxicity; DNMT, DNA methyltransferases; DTC, differentiated thyroid carcinoma; eR, estrogen receptor; FL, follicular lymphoma; 
GBM, glioblastoma multiform; HDAC, histone deacetylase; HDACi, HDAC inhibitor; HL, Hodgkin lymphoma; iL-6, interleukin-6; KTN, karenitecin; LMP, low malignant 
potential; MDS, myelodysplastic syndrome; MM, multiple myeloma; MTC, medullary thyroid cancer; MTD, maximum tolerated dose; NSCLC, nonsmall cell lung cancer; PA, 
phenylacetate; PB, phenylbutyrate; PgP, P-glycoprotein; PK, pharmacokinetic; PMBC, peripheral mononuclear blood cell; PSA, prostate specific antigen; PWBC, peripheral 
white blood cell; QTc, QT interval corrected for heart rate; RAR-α, retinoic acid receptor-α; SAHA, suberoylanilide hydroxamicacid; TARC, thymus and activation regulated 
chemokine; Tg, thyroglobulin; vPA, valproic acid.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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(Table 3, S) for treating melanoma with both Phase I/II 
  trials.108 No VPA/KTN synergistic toxicity was observed. The 
best response was disease stabilization. VPA plus chemo-
immunotherapy was investigated in a Phase II study109 for 
advanced inoperable or metastatic melanoma (Table 3, T), 
HDACi having been previously found to have a tumorigenic 
potential in melanoma.110 Some patients then received dac-
arbazine plus interferon-α with VPA.
The magnesium salt of VPA has been tested in phase I111 
for cervical cancer (squamous and in adenocarcinoma) and 
Phase II112 clinical trials. In the Phase I study (Table 3, U), 
VPA was given per os, and the authors emphasized the 
requirement for new endpoint trials based on biomarker 
analysis113,114 with, in this particular case, H3 and H4 acety-
lation and in vivo HDAC inhibition detection. The Phase II 
study was conducted with hydralazine, a demethylating 
agent,115 (Table 3, V) to overcome chemotherapy resistance 
in refractory solid tumors (cervix, breast, ovarian, and oth-
ers). Partial responses and disease stabilization were the 
best responses.
vorinostat
Vorinostat (suberoylanilide hydroxamicacid [SAHA], 
Zolinza®) has probably been the most studied compound 
in clinical trials on several cancer types. SAHA induces 
differentiation,116 growth arrest,117 or apoptosis at micromolar 
concentrations. Vorinostat is an unselective zinc-binding118 
hydroxamic-acid-type inhibitor of HDAC1, 2, 3, 6, and 8. 
In glioma cells, SAHA induced expression of DR5, TNFα, 
p21Waf1, and p27Kip1 and reduced expression of CDK2, 
CDK4, cyclin D1, and cyclin D2.119 SAHA can induce thy-
roid cancer cell death by caspase-mediated pathways,120 and 
induces G1 and G2-M arrest and apoptosis in several types of 
breast cancer cell lines,121,122 NSCLC,123 and prostate cancer 
cells.124 It potentiates the activity of other molecules like 
Paclitaxel in ovarian cancers.125
Phase I trials have been described for both oral and I.V 
administrations. Escalating I.V . administration126 in solid 
tumors and hematological malignancies (Table 3, W) gave 
hypotension for one schedule. In mesothelioma, with I.V . 
or oral formulations,127 the best responses were partial 
(Table 3, X). An oral formulation for hematologic malignancies 
(Hodgkin’s and others) (Table 3, Y) and solid tumors (mainly 
mesothelioma, prostate, urothelial, thyroid, and renal)128 gave 
one complete response while others were   incomplete. Oral 
twice- or thrice-daily administrations in advanced leukemias 
and MDS (AML, CLL [chronic lymphocytic leukemia], MDS, 
ALL and CML [chronic myelocytic leukemia]) (Table 3, Z)129 
gave two complete responses and two complete responses 
with incomplete blood-count recovery (all with AML treated 
at/below maximum tolerated dose [MTD]).
Phase II clinical trials were mainly proposed with oral 
formulations. A multi-institutional trial130 in women with 
recurrent or persistent epithelial ovarian (Table 3, AA) or 
primary peritoneal carcinoma platinum-resistant/refractory 
gave one partial response. Another multicenter open-label 
oral trial131 investigated measurable, relapsed, or refractory 
breast cancer, NSCLC, or colorectal cancer (Table 3, AB). 
Disease stabilization was observed in eight patients. SAHA 
is tolerated at 200 mg only, in a daily oral schedule for 
14 days–3 weeks. In recurrent and/or metastatic head and 
neck cancer (400 mg every day) (Table AC)132 no confirmed 
responses have been observed. In patients with metastatic 
breast cancer,133 there were no complete or partial responses, 
and the heterogeneity of the recruited patients did not allow 
production of significant statistical results. Eight patients 
were positive for estrogen and/or progesterone receptors, four 
had amplified CerB-2. Fatigue, nausea, diarrhea, and lym-
phopenia were the most frequent clinically significant adverse 
effects. In GBM134 (Table 3 AD), an oral dose of 200 mg 
followed by a 7-day rest period showed that SAHA mono-
therapy is well tolerated with modest single-agent activity. 
Although HDACi were shown to induce cell death and sen-
sitize cells to cytotoxic chemotherapy in thyroid cancer cell 
lines, Woyach et al135 described the lack of therapeutic effect 
of SAHA in patients with metastatic radioiodine-refractory 
thyroid carcinoma in a Phase II study (Table 3, AE). A Phase 
II oral combination therapy was proposed with carboplatin 
(I.V .) and Paclitaxel (I.V .) for advanced solid malignancies136 
(Table 3, AF). Eleven partial responses occurred and seven 
disease stabilizations. The regimen requires drug–drug inter-
action to be determined. Encouraging results were obtained 
in patients with previously untreated NSCLC.
Belinostat
Belinostat (PXD101) is a recent hydroxamic acid HDACi 
that has growth-inhibitory and pro-apoptotic activity in 
several cancer types at submicromolar concentrations,137,138 
and that has been investigated in ovarian cancers.139 It down 
regulates thymidilate synthase, vascular endothelial growth 
factor (VEGF), aurora kinase, and epidermal growth factor 
receptor (EGFR), and up regulates cyclin A. It has been used 
in combination. A gene expression-signature profiling has 
been reported for Belinostat.140 According to publications141 
PKs gave a general 1–2-hour half-life. In early trials, DNA 
fragmentation increased with a combination of 5-FU in Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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HCT116 colon cancer cells in vitro and in both HT-29 and 
HCT116 in xenograft models,142 and also a poly(ADP-ribose) 
polymerase (PARP) cleavage and down regulation of thy-
midylate synthase expression in HCT116. Improved tumor 
reduction was obtained in vivo with mouse HT29 and 
HCT116 xenograft models compared with single compounds, 
validating a rationale for the clinical schedule.
In Phase I treatment of refractory solid tumors by I.V . 
administration (Table 3, AG)143 the caspase-dependent cleav-
age of cytokeratin-18 was determined to measure the level 
of apoptosis.144 Heavily pre-treated patients with advanced 
hematological neoplasia145 (Table 3, AH) were also treated. 
In Phase II trials, investigations of I.V. administration of 
relapsed malignant pleural mesothelioma146 (Table 3, AI) 
indicated that combination strategies or alternate dosing 
schedules might be necessary. In resistant micro-papillary 
ovarian tumors (low malignant potential [LMP]) and epithe-
lial ovarian cancers (EOC) (Table 3, AJ),147 a Phase II trial 
with Belinostat gave partial responses or stable diseases for 
LMP, and stabilized diseases for EOC.
Givinostat
Givinostat (ITF2357) belongs to the hydroxamic acid family 
of HDACi which is very similar to SAHA. It inhibits IL-6 
and VEGF production in stromal cells.148
Two Phase II studies were described for relapsed/refrac-
tory Hodgkin lymphoma (HL) (Table 3, AK). A first oral 
one, gave stable diseases by computed tomography (CT) 
scan that have been associated with a significant reduction 
in fluorodeoxyglucose-positron emission tomography scan 
uptake.149 Galli et al150 developed a Phase II multicenter 
trial in 19 heavily treated patients that were relapsing from 
progressive multiple myeloma (MM) (Table 3, AL). The 
best responses were disease stabilization. This regimen 
appears as unlikely to play a significant role for advanced 
MM, and other combinations with currently used drugs 
should be investigated. A combination with the alkylating 
agent mechlorethamine151 (Table 3, AM) was investigated 
in relapsed/refractory HL.
Panobinostat
Panobisnostat (LBH589) is a hydroxamic acid HDACi, 
which has demonstrated anti-angiogenic and anti-proliferative 
activities in human prostate carcinoma cell PC-3 xenografts 
in vivo, inducing H3 and tubulin acetylation152 in human 
umbilical vascular endothelial cells (HUVEC), which corre-
sponded to G2-M cell cycle arrest and inhibition of HUVEC 
cell proliferation and viability. Non   cytotoxic concentrations 
of Panobinostat inhibited   endothelial tube   formation, matri-
gel invasion, AKT, extracellular   signal-regulated kinase 1/2 
phosphorylation, and chemokine receptor CXCR4 expres-
sion. Association with anti-VEGF therapies should be 
considered. Prince et al have discussed preclinical data on 
Panobinostat and emerging data from Phase I and II studies 
in cancer patients.153
A Phase I study in refractory hematologic malignancies 
(AML, ALL, and MDS) (Table 3, AN)154 with I.V . admin-
istration appeared convenient to obtain anti-leukemic and 
biological effects. In cutaneous T-cell lymphoma (CTCL)47 
with oral formulation (Table 3, AO), the responses ranged 
from disease stabilization to complete remission, showing 
the potential of this molecule in CTCL. In combination with 
Docetaxel155 (Table 3, AP), a microtubule interacting agent 
for castration-resistant prostate cancer, Panobinostat inhib-
ited LnCAP androgen receptor positive prostate cancer cell 
proliferation, potentiated by Docetaxel. Single or combined 
treatments were administered with oral Panobinostat.
Dacinostat
Dacinostat (NVPLAQ824, LAQ) is a hydroxamic acid deriv-
ative similar to Panobinostat.156 It showed anti-neoplastic 
activity and can activate genes that produce cell cycle arrest. 
It acetylates hsp90, inducing proteosomal degradation of Bcr-
Abl and HER-2. Combination of Dacinostat with 5-azaDc157 
in human MDA-MB-231 and MCF-7 breast carcinoma cells 
showed a synergic anti-neoplastic activity for the MDA-MB-
231. For the MCF-7 tumor cells, simultaneous 5-azaDc and 
Dacinostat administration were antagonistic, unseen when 
used in a sequential schedule (5-azaDc first). This is prob-
ably due to interference in the S-phase of Dacinostat since 
5-azaDc is a S-phase specific interfering molecule. Dacino-
stat appeared to be well tolerated in clinical trials. Phase I 
investigations158 in advanced solid tumors included measure 
of HSP72 levels and was consistent with HSP90 inhibition 
(Table 3, AQ). Another group159 reported the same results 
with increased expression of Hsp70 and decreased c-Raf 
levels. The biological importance of these non histones 
mediated effects requires further study. I.V . administration 
for ALL, AML, CLL, CML160 (Table 3, AR) in blast crisis 
or advanced MDS gave some stable diseases.
PCi-24781
PCI-24781 is a broad-spectrum hydroxamic acid-based 
HDACi. PCI-24781 reverses drug resistance in four multi-
drug resistant sarcoma cell lines and synergizes with chemo-
therapeutic agents to enhance caspase-3/7 activity.161Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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In refractory advanced solid tumors162 (Table 3, AS), I.V . 
administration followed by dose escalation was well tolerated. 
Electro cardiac monitoring revealed grade #1 QTcF (QT 
interval corrected for heart rate using Fridericia’s formula) 
prolongation and asymptomatic nonspecific ST and T wave 
changes leading to discontinuation.
entinostat
Entinostat (MS-275, SNX-275) is a benzamide HDACi, 
which promotes expression of genes involved in growth 
arrest and differentiation, like p21 and the maturation marker: 
gelsolin,163 inducing caspase-dependant apoptosis in CLL 
B-cells,164 p21CIP1/WAF1 differentiation or apoptosis 
in human leukemia cells,165 and also tissue growth factor 
(TGF)βII receptor expression in human breast cancer.166 
Reported half-life in animals is about 1 hour, and species-
variable protein binding was reported.167 Half-life in human 
plasma was higher than in animals, which is supposedly to 
be linked to protein binding, as Entinostat was found to be 
80% bound.167
Phase I study in advanced solid tumors or lymphoma by 
oral route168 (Table 3, AT) was reasonably well tolerated. In 
refractory solid tumors and human lymphoid malignancies169 
(Table 3, AU), drug exposure increases linearly with dose. 
In AML170 (Table 3, AV), results showed that Entinostat 
effectively inhibits HDAC in vivo in patients with AML 
and should be further tested, preferably in patients with 
less-advanced disease. Several protocols were designed for 
patients with advanced solid malignancies and lymphomas171 
(Table  3, AW).  PKs  revealed  dose-dependent  and 
dose-proportional increases. Responses were partial   remissions 
and prolonged disease stabilization. In a Phase II study for 
metastatic melanoma (Table 3, AX) with low efficacy 
treatment,172 long-term tumor stabilizations have been 
observed, but no objective responses was assessed.
Mocetinostat
Mocetinostat (MGCD0103)173 is a benzamide selective class 
I/IV HDACi (1, 2, 3, and 11). It inhibits neoplastic growth 
in multiple human tumor xenograft models including colon 
(HCT116, SW48, and Colo205), NSCLC (A549), prostate 
(DU145), pancreatic (PANC1), and vulval epidermal (A431) 
cancer models and does not interact with the potassium 
voltage-gated channel, subfamily H (eag-related), member 2 
(HERG) channel. Gene expression induced by Mocetinostat 
is modest compared with other hydroxamic HDACi.174
In patients with advanced solid tumors175 (Table 3, AY), a 
phase I study gave disease stabilization as the best response. 
IL-6 induction related to HDACi activity has been postulated 
but not confirmed. At the tested doses, Mocetinostat appeared 
tolerable and exhibited favorable PK and PD profiles, as 
well as evidence of target inhibition in surrogate tissues. 
Cytogenetically analyzed patients with AML, MDS, ALL, 
and CML176 (Table 3, AZ) were treated orally. A total of 18 
of the 29 patients had abnormal cytogenetics. PK analyses 
indicated rapid absorption of Mocetinostat. Several admin-
istration schedules have been proposed for advanced leuke-
mias or MDS177 (Table 3, BA). A Phase II study for HL178 
(Table 3, BB) demonstrated significant anti-tumor activity 
in relapsed/refractory post-transplant HL. For 437 patients179 
(Table 3, BC), partial responses were obtained. Extended 
studies are ongoing.
Tacedinaline
The long-known molecule Tacedinaline (CI-994) is a 
  benzamide HDACi similar to MS-275180 with anti-tumor 
activities in HCT-8 colon carcinoma.181 Following Tacedina-
line administration, inhibition of both histone deacetylation 
and cellular proliferation at the G1 to S transition phase of 
the cell cycle are observed.
Oral administration with food intake for solid tumors182 
(Table 3, BD) did not affect the rate or extent of the drug 
absorption. Best responses were partial or stable diseases. 
Advanced solid malignancies (mainly colorectal, pancre-
atic and mesothelioma) were treated in combination with 
Capecitabine183 (Table 3, BE), an FDA-approved compound 
used to treat a variety of cancer. Three treatment protocols 
were implemented. A combination Phase II study with Gem-
citabine184 for advanced pancreatic carcinoma (Table 3, BF) 
gave no improvement.
Depsipeptide
Depsipeptide (Romidepsin, FK228, FR901228) is a cyclic 
tetrapeptide isolated from Chromobacterium violaceum 
which has demonstrated anti tumor activities (A549 lung 
adenocarcinoma, MCF-7 and ZR-75-1 breast adenocarci-
noma, and LOX IMVI melanoma cell lines) and is postulated 
as a Pg-p substrate.185,186 It is considered as a natural HDACi 
prodrug, as its disulfide bond is reduced in vivo to give the 
active species40 and is the only reported sulfur-based HDACi 
used in clinical trials. It received FDA approval for cutaneous 
T-cell lymphoma in 2009. Romidepsin induces growth arrest 
and apoptosis in lung cancer cells.187 Romidepsin induces 
p21-dependent G1 arrest and p21-independent G2 arrest188 
by downregulating cyclin D1 and upregulating cyclin E.189 It 
inhibits c-Myc and Fas ligand expression,190 modulates p53, Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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ErbB1, HER2, and Raf-1 expression in lung cancer cells,191 
increases p21, phosphorylation of Bcl2, and apoptosis in 
human breast cancer cells,192 increases expression of a NaI 
symporter in thyroid carcinoma cells for possible resensi-
tization of radio resistant thyroid cancer,193 and activates 
the caspase 8-mediated apoptosis and down regulates the 
c-FLIP protein.194 Sequential treatments with 5-azaDc facili-
tates cancer cell recognition by T lymphocytes specific for 
  cancer/testis antigen 1B (NY-ESO-1) as a possible option for 
immunotherapy195 or induces tissue factor pathway inhibitor 
(TFPI)-2 expression in cancer cells.196 Initial cardiac toxicity 
was resolved by convenient administration schedules but 
cardiac monitoring is most of the time implemented dur-
ing clinical investigations. Concentrations studies in CLL 
and AML have correlated apoptosis induction and HDAC 
  inhibition. Combination of Romidepsin and DNA demethy-
lating agents is potentiated in ETO positive leukemia cells.197 
A gene signature specific for Romidepsin sensitivity has 
been reported.198 Due to the recent approval of Romidepsin 
in CTCL, all early published clinical trials for this disease 
are not discussed.199,200 Romidepsin induced MDR-1 gene 
expression in several cancer cell lines.
A Phase I study in advanced, incurable cancers201 
(Table 3, BG) indicated that further clinical trials are 
warranted. Used for advanced or refractory neoplasms202 
(Table 3, BH), elimination half-life was 8.1 hours. In CCL 
and AML203 (Table 3, BI), intravenous treatment gave no 
responses. Romidepsin effectively inhibits HDAC in vivo 
in patients with CLL and AML, but future studies should 
examine alternative administration routes. In refractory 
or recurrent solid tumors204 (Table 3, BJ), DLTs were not 
associated with changes in troponin levels or evidence of 
ventricular dysfunction, transient asymptomatic sick sinus 
syndrome and hypocalcemia. For MDS and AML205 (Table 3, 
BK), intravenous administration gave no significant cardiac 
toxicity. Romidepsin therapy can be administered with 
acceptable short-term toxicity. Gastrointestinal symptoms 
and fatigue seemed to be treatment-limiting after multiple 
cycles. Phase II performed on refractory renal cell cancer206 
(Table 3, BL), I.V., gave classical but serious toxicities. 
Two patients developed a prolonged QT interval, one patient 
developed grade 3 atrial fibrillation and tachycardia, and 
there was one sudden death. In metastatic neuroendocrine 
tumors207 (Table 3, BM), adverse events were ventricular 
tachycardia and prolonged QT, possibly resulting in a sudden 
death, terminating the study prematurely. Romidepsin has 
serious cardiac adverse events, and risks need to be compre-
hensively evaluated. In lung cancers (NSCLC and SCLC) 
(Table 3, BN),208 Romidepsin was not appropriate. This study 
presented an in depth gene expression profiling.
Conclusion
A number of clinical trials have been completed and many 
others are ongoing using HDACi as single agents and in 
combination with radiotherapy and/or chemotherapy for the 
treatment of various hematological and solid malignancies 
with some promising early results. Vorinostat is the most 
established HDACi, and was approved in October 2006 by the 
FDA for the treatment of advanced forms of cutaneous T-cell 
lymphoma that have failed multiple other systemic treatment 
options. Significant single agent activity for Romidepsin 
has also been demonstrated in peripheral cutaneous T-cell 
lymphoma, and encouraging results have also been seen in 
HL with Mocetinostat. From the trials conducted, it is also 
clear that a major clinical advantage is that HDACi are well 
tolerated in the majority of patients. The future of HDACi lies 
in designing rational combination therapies. The sequence 
of drug administration may be of paramount importance to 
avoid antagonistic effects. The possibility of drug–drug inter-
actions and enhanced toxicities is to be considered. HDACi 
are also evaluated in non cancerous pathologies like AIDS, 
graft versus host diseases, and polycythemia verae. Very 
soon, SIRT activators could find therapeutic applications in 
lung interstitial diseases. Like for the kinase inhibitors, more 
selective third generation HDACi are sought, yet specific 
tests remain to be designed to screen for bioactivity in vitro 
and in vivo.211
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